Latest news with #MDAX
Business Wire
31-07-2025
- Business
- Business Wire
GEA Raises Forecast for Fiscal Year 2025 and Provides Positive Outlook
DUESSELDORF, Germany--(BUSINESS WIRE)--Due to a very positive operating performance in the first 6 months and expectations for the remainder of the financial year 2025, GEA Group Aktiengesellschaft is raising all guidance parameters based on preliminary figures as follows: Organic sales growth 2 to 4 percent (previously 1 to 4 percent), EBITDA-margin before restructuring expenses 16.2 to 16.4 percent (previously 15.6 to 16.0 percent) and ROCE 34 to 38 percent (previously 30 to 35 percent). The company will publish its complete statement for the 2nd quarter (half-year financial report) on August 7, 2025. 'Our positive development continues. The additional improvements are broad-based, supported by a favorable order situation as well as margin improvements and efficiency gains across the Group. Once again, we are thus demonstrating our strength in executing on our plans,' said GEA CEO Stefan Klebert. Alongside improving the profitability indicators EBITDA margin before restructuring expenses and ROCE, GEA also increased order intake and revenues on an organic basis compared to the prior-year quarter. This was particularly driven by a strong base business. The large order with a volume of between EUR 140 million and EUR 170 million announced by GEA on July 29 will only be booked in the second half of this year. 'Despite the current environment, GEA continues to perform very positively. We anticipate further interesting projects of all sizes in the second half of the year and expect to significantly accelerate our revenue growth in 2026 while further increasing profitability. Against this background, we are confirming our Mission 30 growth and profitability targets,' GEA CEO Stefan Klebert added. NOTES TO THE EDITOR More information about GEA To the GEA Media Center Follow GEA on LinkedIn, YouTube ABOUT GEA GEA is one of the world's largest suppliers of systems and components to the food, beverage and pharmaceutical industries. The international technology group, founded in 1881, focuses on machinery and plants, as well as advanced process technology, components and comprehensive services. For instance, every second pharma separator for essential healthcare products such as vaccines or novel biopharmaceuticals is produced by GEA. In food, every fourth package of pasta or every third chicken nugget are processed with GEA technology. With more than 18,000 employees, the group generated revenues of about EUR 5.5 billion in more than 150 countries in the 2024 fiscal year. GEA plants, processes, components and services enhance the efficiency and sustainability of customers' production. They contribute significantly to the reduction of CO2 emissions, plastic usage and food waste. In doing so, GEA makes a key contribution toward a sustainable future, in line with the company's purpose: 'Engineering for a better world.' GEA is listed on the German MDAX, the European STOXX® Europe 600 Index and is also a constituent of the leading sustainability indices DAX 50 ESG, MSCI Global Sustainability and Dow Jones Best-in-Class World. More information can be found online at pr@
Yahoo
30-07-2025
- Business
- Yahoo
Evotec and Sandoz Evolve their Strategic Partnership and Agree on Potential Sale of Just - Evotec Biologics Toulouse Site
Evotec SE and Sandoz AG signed a non-binding term sheet on a planned sale of Just - Evotec Biologics EU in Toulouse to Sandoz Under the proposed deal Evotec would transfer biosimilar manufacturing capabilities to enable Sandoz to produce biosimilar medicines using Just - Evotec Biologics' advanced continuous manufacturing technology The deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition will include further technology related consideration, future development revenues, milestones and product royalties Planned transaction marks major milestone in Evotec's strategy to create asset-lighter business model leveraging high-margin offerings, with Just - Evotec Biologics remaining core business for Evotec Transaction is expected to immediately improve Evotec's short-, mid-, and long-term revenue mix, profit margins, and capital efficiency HAMBURG, DE / / July 30, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced the signing of a non-binding agreement with Sandoz AG (SIX:SDZ)(OTCQX:SDZNY) regarding the potential sale of Just - Evotec Biologics EU, which owns the biologics manufacturing facility in Toulouse, France, and to grant access to its proprietary platform for integrated development and advanced continuous manufacturing of biologics via a technology license. The site has been customised and dedicated entirely to Sandoz since July 2024, and the transaction is a natural progression in an already successful partnership. Closing of the planned transaction remains subject to completion of the relevant information and consultation processes with employees and their representatives, final contractual agreements and to meeting regulatory requirements, expected in the fourth quarter. Further deal terms will be disclosed after successful signing of the contracts. Execution on strategy to create an asset-lighter business model for Just - Evotec Biologics The agreement marks a milestone in Evotec's new strategy to drive sustainable and profitable growth. A key pillar of this strategy is the transition to an asset-lighter and capital-efficient model that can better leverage its technology & IP and scale its service offerings. Under the proposed terms of the transaction, Sandoz would assume full ownership of the Just - Evotec Biologics Toulouse site, while Evotec would retain short-, mid-, and long-term economic upside through revenue, milestones and royalty optionality. The planned deal terms include the purchase price of the site for around US$ 300 m in cash, and in addition would include further technology related consideration, future development revenues, milestones and product royalties. The planned deal would immediately improve Evotec's revenue mix, profit margins, and capital efficiency. Additionally, the agreement is testament for Evotec's ability to leverage its technology advantage to shape a new segment in a fast-growing market. Continuation of strategic collaboration The planned transfer of Just - Evotec Biologics' biosimilars manufacturing facility, a dedicated single-customer site, including proprietary platform for integrated development and advanced continuous manufacturing, is the natural next step in the multi-year strategic partnership between Evotec and Sandoz. It follows the agreement in July 2024 to grant Sandoz long-term commercial supply access to the facility. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: "We are excited about the evolution of our strategic partnership. Today's agreement marks a significant milestone in Evotec's new strategy to refocus on its core strengths and deliver sustainable profitable growth. By leveraging Just - Evotec Biologics' capabilities as a scalable technology provider while moving to a more capital efficient model, we are well positioned to shape a new segment in the biologics manufacturing market and expand the scope of our partner base." Dr Linda Zuckerman, EVP and Global Head of Just - Evotec Biologics, said: "We are thrilled to see our technology and vision further validated through this transaction. Just - Evotec Biologics and Sandoz are united in our missions to broaden global access to life-changing biotherapeutics. Our perfusion-based continuous manufacturing platform plays a pivotal role in achieving this mission, unlocking greater efficiency, scalability, and agility." About Evotec SEEvotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn . Forward-looking statementsThis announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker BraunEVP Head of Global Investor Relations & SOURCE: Evotec SE View the original press release on ACCESS Newswire
Associated Press
21-07-2025
- Business
- Associated Press
Evotec Adjusts Revenue Guidance and Confirms Profit Guidance Anticipating a More Profitable Revenue Mix
HAMBURG, DE / ACCESS Newswire / July 21, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ:EVO) today announced that it has updated its revenue guidance for the fiscal year 2025. R&D and adjusted EBITDA related guidance elements remain unaffected. For the current fiscal year, the Company expects revenues in the range of € 760 - 800 m (versus previously € 840 - 880 m; 2024: € 797.0 m); R&D expenditures are expected in a range of € 40 - 50 m (unchanged; 2024: € 50.8 m); Adjusted EBITDA 1 is expected to reach € 30 - 50 m (unchanged; 2024: € 22.6 m). Outlook 2028 remains unchanged with a targeted Group revenue CAGR 2024-2028 in a range of 8 - 12% and an expected adj. EBITDA margin above 20% by 2028. 1 Excluding potential costs related to the transformation program in 2025 CAGR: Compound annual growth rate In April, Evotec announced its new strategy for sustainable and profitable growth. A key element of this strategy is the refocused growth path, building on existing and new partnerships and further strengthened by leveraging its capabilities as a scalable technology and service provider. This also includes pivoting to a capex lighter model. The Company expects this value creation strategy to result in tangible results earlier than initially expected, driven by stronger than planned revenue contributions from high-margin technology license deals. After generating revenues below expectations in H1 2025, the Shared R&D base business is expected to continue to operate in a challenging market in the second half of 2025. Dr Christian Wojczewski, Chief Executive Officer of Evotec, said: 'Our strategy for sustainable and profitable growth is progressing as planned. Strong demand for higher margin businesses reflects the strength of our platforms and validates the decisions we've made around focus, partnerships, and capital efficiency. While some parts of our business continue to operate in a challenging market environment, the execution of our Priority Reset, and new strategy gives us confidence that we are well-positioned to deliver on our long-term ambitions.' The changing revenue mix is expected to positively influence the margin profile of the Evotec Group. In parallel, Evotec accelerated the implementation of its Priority Reset focused on ensuring sustainable profitable growth and right-sizing the business. The cost savings generated through these transformation efforts are now expected to exceed targets announced during the Q1 2025 results call on 06 May 2025. About Evotec SE Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. For additional information please go to and follow us on X/Twitter @Evotec and LinkedIn. Forward-looking statements This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as 'anticipate,' 'believe,' 'could,' 'estimate,' 'expect,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'should,' 'target,' 'would' and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based. For further information, please contact: Investor Relations Volker Braun EVP Head of Global Investor Relations & ESG [email protected] SOURCE: Evotec SE press release
The Market Online
04-06-2025
- Business
- The Market Online
With gold over USD 3,400 - 100% gains in no time: Gerresheimer, Desert Gold, Hensoldt and RENK
Rumors about Jerome Powell's resignation were circulating at the beginning of the week. Described as very 'hawkish,' meaning he strictly aligns interest rates with inflation, he is an uncomfortable contemporary for President Donald Trump. The US administration needs a lot of money to get the outdated infrastructure and the entire economy back on track. Numerous campaign promises for a flourishing America can only be fulfilled by the flamboyant frontman if sufficient funds are available. This is a difficult undertaking due to the very high level of government debt. The credit rating agency Moody's is not intimidated by the president's threats and recently downgraded the US credit rating by one notch to AA1. Triple-A status is now history. This is a perfect setup for gold, with the precious metal rising again to over USD 3,400. Where are the opportunities for investors? Gerresheimer shareholders are currently experiencing just how quickly a share price can plummet. The specialty packaging manufacturer's shares tumbled by more than 25% at the beginning of the week and only found solid ground again at around EUR 47. This marks a three-year low for the MDAX stock, and no significant recovery is visible so far. The current profit warning has a painful impact on the original forecast for 2025, which now seems unachievable for the time being. Instead of moderate growth in net profit, Gerresheimer now expects a low double-digit decline. As a precautionary measure, the dividend for 2024 will be almost eliminated, with only 4 cents being distributed instead of EUR 1.25. Nevertheless, revenue is expected to increase slightly with an EBITDA margin of approximately 20% on average for the year. Analysts reacted coolly, with JPMorgan lowering its price target from EUR 122.50 to just EUR 108 but maintaining its 'Overweight' rating. Jefferies remains at 'Buy' and has left its price target at EUR 86. The German SME appears to be attracting much interest, as the Company has been in the spotlight of financial investors for years. Recently, rumors of an imminent takeover by Warburg Pincus and KPC Capital Partners caused the share price to rise to over EUR 66. On the LSEG platform, the 12-month consensus is currently EUR 58.50. The share price was trading above EUR 120 in 2023 and now has a single-digit P/E ratio for the next three years. That is cheap! Desert Gold – There is a lot to look forward to With Moody's downgrade of the US credit rating, 30-year bond yields have swung to over 5%. Historically, this level has always been perfect for a rise in the gold price, as inflation concerns cause investors to flee to the yellow metal. The persistent claim that gold pays no interest is clearly refuted by an annual return of over 9% since 2000. Gold has regained strength solely due to the devaluation of the US dollar and the corresponding loss of purchasing power. Even central banks are constantly buying, with Switzerland, China, Russia, and India standing out on the list of buyers. It is also gradually becoming apparent that US bonds are no longer the first choice for foreign exchange reserves. China has already sold over 30% of its holdings and is now only a minor subscriber to new issues. This is a difficult situation for the highly indebted US. Things are developing as hoped for Canadian explorer Desert Gold Ventures (TSXV:DAU). The Preliminary Economic Assessment (PEA) is underway, which means that the junior company will soon be able to start small-scale leach-testing. The promising properties, covering an area of approximately 440 square kilometers, are located in the Senegal-Mali Shear Zone (SMSZ), also known as 'Elephant Country.' The term describes the estimated 26 million ounces of reserves held by major players Barrick, B2Gold, Endeavour, Allied Gold, Hummingbird, Resolute, and BCM, which have only been partially explored or mined to date. Desert Gold has already identified 1.1 million ounces of gold near surface with 95,000 meters of drilling. CEO Jared Scharf and his team of geologists are confident that the upcoming evaluations will reveal an even higher value. Rumor has it that several high-ranking visitors have already visited Desert Gold's properties. With gold prices so high, the excitement is growing every day! When will a major player snap up the last remaining land in 'Elephant Country'? Desert Gold (DAU) shares have posted double-digit gains this year, but the next surge could be just around the corner. For some time now, the price of the approximately 240 million outstanding shares has been moving sideways between CAD 0.07 and CAD 0.08. With a market capitalization of around CAD 18 million, Desert Gold is significantly undervalued compared to its peers. A speculative buy! Hensoldt and RENK – Steep, steeper, doubled In addition to the gold market, defense stocks are currently booming. The never-ending conflicts in Ukraine and the Middle East are fueling demand for security and rearmament in NATO countries, which had tended to invest in disarmament during the long 70-year period of peace. Now, there is a dramatic 180-degree turnaround, with even former pacifists in the political landscape now advising billions in investments in military technology. The German Armed Forces alone are expected to receive a budget of more than EUR 100 billion over the next five years. For European defense stocks, this is almost daily grist for the mill. Hensoldt and RENK have gained 100% and 180%, respectively, in the last three months. Looking at the fundamental figures, analysts are currently unable to adjust their estimates to the incoming order situation. JPMorgan hastily adjusted its price target for Hensoldt from EUR 50 to EUR 110 to avoid looking completely out of touch in the analyst rankings. Other research houses are somewhat more conservative, setting price targets between EUR 45 and EUR 85, resulting in an average of EUR 67. However, everything has already been equalized, with Hensoldt exceeding the EUR 100 mark at the beginning of the week. According to the LSEG platform, the estimated 2025 P/E ratio is now 54, and the price-to-sales ratio (P/S) is almost 5. The picture is similar at RENK, where the Company is emulating industry leader Rheinmetall. Since investor Triton placed the stock at EUR 16 in 2024, the price has quintupled. The estimated 2025 P/E and P/S ratios are 62 and 6.3, respectively – what more can be said? Perhaps the order volume is so overwhelming that price hikes are fully justified. In this case, taxpayers do not get a say – the newly elected Bundestag has already approved the largest wave of defense investment in modern history by a majority vote. Prosperity and adversity are often close together. Looking back over the last three months, the stock market favored defense and gold stocks. RENK and Hensoldt are clearly on the rise, and Desert Gold has also seen double-digit growth. Only Gerresheimer was sent into a tailspin due to a profit warning. (Source: LSEG on June 3, 2025) Due to ongoing geopolitical tensions, defense stocks are currently setting the tone. Meanwhile, long-term interest rates are rising in the background, which is also pushing up bond yields. Junior explorer Desert Gold is heading into an interesting year of transformation – with a valuation of CAD 18 million, or roughly USD 12 per ounce of gold in the ground, an acquisition is not unlikely. Conflict of interest Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as 'Relevant Persons') currently hold or hold shares or other financial instruments of the aforementioned companies and speculate on their price developments. In this respect, they intend to sell or acquire shares or other financial instruments of the companies (hereinafter each referred to as a 'Transaction'). Transactions may thereby influence the respective price of the shares or other financial instruments of the Company. In this respect, there is a concrete conflict of interest in the reporting on the companies. In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships. For this reason, there is also a concrete conflict of interest. The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies. Risk notice Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such. The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user. The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use. This is sponsored content issued on behalf of Desert Gold Ventures Inc., please see full disclaimer here.
Yahoo
02-06-2025
- Business
- Yahoo
German watchdog finds no abuse in companies' pre-results calls with analysts
By Tom Sims FRANKFURT (Reuters) -An investigation by Germany's financial watchdog has found no reason to change companies' practice of communicating with analysts before publishing results, following media concerns about the potential disclosure of insider information. Regulators have taken a closer look at so-called pre-close calls after media reports highlighted an apparent connection between high volatility in share prices and the communication with analysts. Germany's BaFin watchdog disclosed at a conference on Monday the findings of a study it began last year. Details will likely be published this week. "We do not currently see any systematic problems with the execution of pre-close calls," Christoph Schell, a BaFin official who studies market surveillance and abuse, said at the conference. Strong price reactions are isolated cases, and there is no need to tighten rules around the calls, he added. Last year, the European Union's securities watchdog warned that companies should not share market-sensitive information with external analysts ahead of their financial statements. The practice of pre-close calls is widespread - not just in Germany. It is typically communication before the publication of financial statements, between a company and analysts who generate research, forecasts and recommendations on the company's shares and bonds. Supporters say the calls contribute to the orderly functioning of markets. Schell said that BaFin found in its study that 63% of companies listed on Germany's DAX index of blue-chips and the MDAX of smaller companies hold pre-close calls. More than 90% of those companies conduct individual chats with analysts, he said. BaFin found that 70% of the market trading around calls it investigated showed no significant market reaction, while only 10% did. "We have investigated these cases and have so far found no evidence of any unauthorized disclosure of insider information," Schell said. He added that companies should nevertheless be as transparent as possible, by announcing the calls on their websites and holding them in a group format rather than individually.
